Recent News

• 01.20.2026 - Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
• 11.06.2025 - Rein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPF
• 11.03.2025 - Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 10.09.2025 - Rein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis
• 09.17.2025 - Rein Therapeutics Announces Publication of New Translational Data in iScience on Company’s Novel Therapy for Idiopathic Pulmonary Fibrosis

Recent Filings

• 01.16.2026 - 8-K Current report
• 12.11.2025 - 8-K Current report
• 11.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2025 - EX-99.1 EX-99.1
• 11.03.2025 - 8-K Current report
• 10.28.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.24.2025 - 8-K Current report
• 10.09.2025 - 8-K Current report
• 10.09.2025 - EX-99.1 EX-99.1